|Home | About | Journals | Submit | Contact Us | Français|
To examine the association of baseline and lifetime ethanol intake with cancer of the pancreas in the European Prospective Investigation into Cancer and Nutrition (EPIC).
Included in this analysis were 478,400 subjects, of whom detailed information on the intake of alcoholic beverages at baseline and over lifetime was collected between 1992 and 2000. During a median follow-up time of 8.9 years, 555 non-endocrine pancreatic cancer cases were observed. Multivariate Cox proportional hazard models were used to examine the association of ethanol intake at recruitment and average lifetime ethanol intake and pancreatic cancer adjusting for smoking, height, weight, and history of diabetes.
Overall, neither ethanol intake at recruitment [relative risk (RR) = 0.94, 95% confidence interval (CI) 0.69–1.27 comparing 30+ g/d vs. 0.1–4.9 g/d] nor average lifetime ethanol intake (RR=0.95, 95% CI 0.65–1.39) were associated with pancreatic cancer risk. High lifetime ethanol intake from spirits/liquor at recruitment tended to be associated with a higher risk (RR=1.40, 95% CI 0.93–2.10 comparing 10+ g/d vs. 0.1–4.9 g/d), but no associations were observed for wine and beer consumption.
These results suggest no association of alcohol consumption with the risk of pancreatic cancer.
Pancreatic cancer is one of the most lethal cancers with a one-year survival rate of less than 20% . Its incidence varies worldwide with high rates in the US, Australia, and Europe  suggesting that a certain proportion of pancreas cancer occurrence is due to environmental factors. However, only few environmental risk factors have been clearly identified so far. Smoking is the major established risk factor [2, 3]. In addition, excess body weight [4, 5], history of (type-2) diabetes mellitus , elevated blood levels of glucose [7, 8], and chronic hyperinsulinemia  have been associated with pancreatic cancer risk. Some epidemiological studies have also reported associations of increased pancreatic cancer risk with low intakes of fruit and vegetables , or elevated intakes of red and/or processed meat .
Alcohol consumption is an important determinant of chronic pancreatitis, a risk factor of pancreatic cancer [11, 12]. Thus, several prospective studies have examined the association between alcohol consumption at the time of enrolment into the studyand pancreatic cancer risk [13–26]. No statistically significant associations of alcohol consumption with pancreatic cancer risk were observed in the largest of these cohort studies, each including more than 100 cases [16, 18, 21–25, 27], and numerous case-control studies (summarized in ) but three cohort studies noted a statistically significantly higher risk of pancreatic cancer among consumers of alcoholic beverages compared with non-consumers [15, 17, 20]. In contrast, lifetime alcohol consumption habits have rarely been investigated [25, 28, 29].
Since differences in alcohol consumption habits concerning amount of alcohol consumed and type of alcoholic beverage might contribute to inconsistent findings between studies, it is of interest to examine this question in a large European study with a wide range of daily alcohol consumption. The European Prospective Investigation into Cancer and Nutrition (EPIC) offers the opportunity to examine the association between ethanol intake and pancreatic cancer risk in a more detailed way than it has been done before, especially because of its detailed assessment of lifetime alcohol consumption in most of the participating study centres.
EPIC was conducted in 23 centres in 10 European countries . 521,448 participants were recruited for this study, mostly from the general population. Exceptions were the French cohort, which encompasses female members of a health insurance for school and university employees, and the Spanish and Italian centres, which include blood donors. In Utrecht, breast cancer screening participants were recruited for the study, and also the Florence cohort includes participants of a breast cancer screening program. In Oxford, half of the cohort members are ‘health conscious’ subjects from England, Wales, Scotland, and Northern Ireland. The cohorts of France, Norway, Utrecht, and Naples consist of women only .
Of 521,448 participants, we excluded 27,094 prevalent cancer cases and subjects with missing follow-up information, 6,220 subjects without dietary or non-dietary information, and 9,674 subjects with an extreme ranking ratio for energy intake versus energy expenditure (top and bottom 1%). Finally, 60 pancreatic cancer cases were excluded from the analysis because of having a malignant tumor at another site prior to their pancreatic tumor or having a (neuro)endocrine tumor. Thus, the current analysis was based on 478,400 EPIC-participants including 555 incident non-endocrine pancreatic cancer cases. Lifetime ethanol intake was assessed only in some EPIC centers (see page 6) and was, thus, based on 402 pancreatic cancer cases among 363,970 participants.
Diet over the previous twelve months was assessed using dietary assessment instruments that were specifically developed for each participating country. Food frequency questionnaires were used in France, Varese, Turin, Florence, Ragusa, Naples, Spain, Germany, Greece, Great Britain, The Netherlands, Umea, Denmark, and Norway. In Malmö, a non-quantitative FFQ was combined with a 14 day dietary record on hot meals. Baseline ethanol and energy intake were calculated on the basis of these dietary assessment instruments . Participants reported on how many standard glasses of beer and/or cider, wine, sweet liquor, distilled spirits, or fortified wines they consumed per day or per week during the 12 months prior to recruitment. Ethanol intake was calculated based on the average glass volume and ethanol content for each type of alcoholic beverage .
Information on past alcohol consumption was assessed as glass(es) of beverage consumed per week at different ages (20, 30, 40, and 50 years of age) in the lifestyle questionnaire. This information was assessed in most, but not all, study centres and was available for 364,789 participants (76.1% of the subjects included in the analysis). No information on alcohol consumption in the past was available from Naples (Italy), Bilthoven (The Netherlands), Sweden, and Norway. Consumption of alcoholic beverages at different ages and at recruitment was the basis to calculate average lifetime ethanol intake. Average lifetime ethanol intake was determined as a weighted average of the intake at different ages, with weights equal to the total subject specific time under investigation.
Information on history of prevalent diseases such as diabetes mellitus and on lifetime history of consumption of tobacco products was assessed including questions on smoking status (current, past, or never smoker), type of tobacco (cigarettes, cigars, or pipe), number of cigarettes currently smoked, and age when participants started and, if applicable, quit smoking. Height and weight were measured in all EPIC centres except for France, Norway, and Oxford, for which self-reported height and weight was assessed via questionnaire .
Cancer diagnoses were based on population cancer registries in Denmark, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom. An active follow-up through study subjects as well as next-of-kin information, the use of health insurance records and cancer and pathology registries were used in France, Germany, and Greece. Mortality data were also obtained from either the cancer or mortality registries at the regional or national level. Participants from centres that relied on registry data that have been reported to IARC were censored between December 2002 and December 2005, depending on the study center. For Germany and Greece, the end of the follow up was considered to be the last known contact, the date of diagnosis, or the date of death, whichever came first.
Pancreatic cancer incidence data were coded according to International Classification of Diseases-Oncology (ICD-O) 2nd edition and included all invasive pancreatic cancers that were coded as C25 (C25.0–C25.3, C25.7–C25.9). All self-reports by the study participants were then confirmed by a review of the appropriate medical records. Of all 555 exocrine pancreatic tumors, 372 (67%) were microscopically confirmed, based on histology of the primary tumor (n = 211), histology of the metastasis (n = 34), cytology (n = 92) or autopsy (n = 35). For 33% of pancreatic tumors microscopic confirmation was missing and diagnosis was based on clinical symptoms, physical examination and imaging results.
Participants were categorized according to their total ethanol intake at baseline and the average lifetime ethanol intake. Subjects were categorized into five groups (0, 0.1–4.9, 5.0–14.9, 15.0–29.9, or ≥ 30 g/day). The low ethanol intake of 0.1–4.9 g/day was chosen as the reference category such as to have a sufficiently high number of cases in the reference category. Subjects were also categorized by their intake of ethanol from beer, wine, and spirits & liquors.
Cox proportional hazards regression was used to examine the association of ethanol intake with pancreatic cancer. Age was used as the primary time variable in the Cox models. Time at entry was age at recruitment, exit time was age when participants were diagnosed with cancer, died, were lost to follow-up, or were censored at the end of the follow-up period. The analyses were stratified by sex, by centre to account for centre effects such as follow-up procedures and questionnaire design, and by age at recruitment to account for violations of the proportional hazard assumption. To adjust for smoking habits and history, we included current tobacco smoking status (never smoker; current smoker with 1–14, 15–24, or 25+ cigarettes/day; former smoker who stopped less than 10 years ago, former smoker who stopped 10 or more years ago; smoking status unknown). Additionally, weight and height at baseline (continuous) were included in the models. Using body mass index instead of height and weight did not alter the results. Since diabetes is strongly associated with pancreatic cancer risk and in an U-shaped manner with ethanol intake , we also included history of diabetes into our multivariate models. Energy intake is a suspected risk factor for pancreatic cancer and also related to ethanol intake but the risk estimates were virtually unchanged when we adjusted for energy intake from non-alcohol sources. The same was true when we ran models adjusting for physical activity at work and education. We tested for interaction of sex, smoking status (never, former, current smoker, missing), and body mass index (BMI; <25 kg/m2, ≥25 kg/m2) with ethanol intake by including a cross-product term along with the main effect terms for each in the Cox regression model. The statistical significance of the cross-product term was evaluated using the likelihood ratio test. Heterogeneity between categories of ethanol intake and between countries was assessed using likelihood chi-square tests. Since undiagnosed disease at baseline may have led to changes in ethanol intake, models excluding the first 2 years of follow-up were run for ethanol intake at baseline. All analyses were conducted using SAS version 9.1 (SAS Institute, Cary, North Carolina).
Within a median follow-up time of 8.9 years (interquartile range 7.6–10.5), 239 pancreatic cancer cases were observed among men and 316 among women. Median age at pancreatic cancer diagnosis was 63.3 (interquartile range 57.9–69.0) years. Male non-drinkers at baseline were most common in the Spanish and least common in the Danish centres (Table 1). In women, non-drinking was much more frequent than in men. More than half of the female participants of the Spanish cohorts did not consume alcoholic beverages at baseline. Median ethanol intake among men was highest in the Spanish and Italian centres, whereas median intake among women was highest in the Danish centres. Baseline characteristics by categories of ethanol intake at baseline are shown in Table 2. Male and female non-consumers of alcoholic beverages were older than consumers, differed by education and smoking habits, and had a higher prevalence of diabetes at baseline. Baseline characteristics were similar when considering only those participants for whom information on lifetime ethanol intake was available (data not shown). In our cohort, 29.4% of cases were current smokers (compared with 22.4% among non-cases), the percentage of subjects with diabetes with 6.9% in cases and 2.7% in non-cases.
We did not observe any statistically significant association between ethanol intake at recruitment and pancreatic cancer risk; these results were similar in the simple and the multivariately adjusted models besides slightly different risk estimates in the highest category of ethanol intake (Table 3). No statistically significant heterogeneity between categories of ethanol intake at baseline was observed (p=0.60). Per 10 g intake of ethanol at recruitment, we observed an RR=1.00 (95% CI 0.96–1.05; p-trend=0.96). The observed associations did not change when we excluded the first two years of follow-up: the RR for individuals with an intake of 30+ g/day was 0.92 (95% CI 0.66–1.30) compared with subjects with an intake of 0.1–4.9 g/day (data not shown). Excluding 183 cases that were not histologically confirmed did not appreciably change our results (data not shown). The same was true for the exclusion of participants with a diagnosis of type-2 diabetes (data not shown). No statistically significant heterogeneity between countries (p=0.67) or interaction bysex, smoking status, or BMI was observed (all p-interaction >0.05).
Former drinkers did not have a statistically significantly different risk of pancreatic cancer than never drinkers (RR=1.21, 95% CI 0.68–2.16). Therefore, we did not differentiate between former and current drinkers in our analysis of lifetime alcohol consumption. We did not observe a statistically significant association between average lifetime ethanol intake and pancreatic cancer risk (Table 3); no statistically significant heterogeneity between categories of ethanol intake was observed (p=0.66). No statistically significant effect modification by sex, smoking status, or BMI was found (all p-interaction >0.05) nor was there any indication of heterogeneity of effects by country (p=0.63). We observed a correlation of r=0.66 (p<0.0001) between alcohol intake at recruitment and average lifetime alcohol consumption.
Results for ethanol intake from different types of alcoholic beverages, which were mutually adjusted for each other, are shown in Table 4. Neither wine nor beer consumption were significantly associated with the risk of pancreatic cancer. For spirits/liquor consumption at baseline, we observed an increased risk of pancreatic cancer in participants with a daily intake of 5.0–9.9 g/day compared with subjects with an intake of 0.1–4.9 g/day (RR=1.46, 95% CI 1.07–1.99; Table 4). However, the risk was not elevated in subjects with an intake of 10+ g/day. For average lifetime consumption of spirits and liquor, we also noted an increased risk of pancreatic cancer in subjects with an average lifetime daily intake of 5.0–9.9 and 10+ g ethanol from spirits and liquor that, however, did not reach statistical significance in the multivariate model (RR=1.30, 95% CI 0.91–1.85 and RR=1.40, 95% CI 0.93–2.10, respectively). Since subjects who consume high amount of spirits and liquor are also often smokers, we repeated the analysis in subjects who never smoked or quit 10 or more years before baseline (n=318 cases) to minimize residual confounding by smoking, which did not strongly change the results (10+ g vs. 0.1–4.9 g ethanol at baseline RR=1.51, 95% CI 0.85–2.70 in the multivariate model). No statistically significantly heterogeneity between countries was observed for any of the alcoholic beverages (all p-heterogeneity>0.05), nor was effect modification found by sex, smoking status, or BMI (all p-interaction >0.05).
In this large prospective cohort study with 555 incident pancreatic cancer cases, we neither observed a statistically significant association of ethanol intake at baseline nor of average lifetime ethanol intake with pancreatic cancer. This was true, even after excluding the first two years of follow-up.
Alcohol consumption has been suspected as a cause of pancreatic cancer because it is an important determinant of some forms of chronic pancreatitis, which is a risk factor of pancreatic cancer [11, 12]. Also, acetaldehyde, the first metabolite of ethanol, is a well-established carcinogen . Further, fatty acid ethyl esters (non-oxidative ethanol metabolites) accumulate in the pancreas and may induce pancreatic injury [34, 35], and ethanol might affect the metabolism of carcinogens and, e.g., induce human liver cytochrome P450 2E1, which, then, can activate pre-carcinogens . In the largest cohort study with more than one million participants and 3,751 pancreatic cancer deaths in 14 years of follow-up, no statistically significant association between alcohol consumption and pancreatic cancer risk was noted (comparing > 1drink/day vs. none: men RR=1.0, 95% CI 0.9–1.1, women RR=0.9, 95% CI 0.8–1.1) , a result confirmed by other large cohort studies [16, 18, 21, 23, 24] including the present study. Two smaller cohort studies reported a statistically significantly increased risk of pancreatic cancer among consumers of alcoholic beverages compared with non-consumers [15, 17], and in the Iowa Women’s Health Study, a statistically significant 65% higher pancreatic cancer risk was observed in women who consumed more than two drinks per week compared with non-consumers . Differences between studies might be due to different alcohol consumption patterns, differential errors in alcohol consumption assessment, differences in confounder patterns, such as smoking habits, and/or sample size and power of the study.
In contrast to current alcohol consumption, the association with alcohol consumption in the past and lifetime alcohol consumption has been investigated less frequently. Only one cohort study  examined the association of years of drinking and the cumulative amount of alcoholic beverage drunk over time with pancreatic cancer risk but no association was observed for either variable. Further, in two case-control studies, no statistically significant association between past alcohol consumption was seen when compared with non-drinkers [14, 18]. This is similar to the result in this study within EPIC, where no statistically significant association was observed between average lifetime ethanol intake and pancreatic cancer risk.
We did not observe a statistically significant association of ethanol intake from wine with pancreatic cancer risk; results from previous studies are inconsistent [14, 20,28], with one study reporting an inverse association with white wine (but not red wine) consumption. For intake of ethanol from spirits/liquor, we observed positive, although not entirely consistent, associations with pancreatic cancer risk. Three [16, 17, 20] out of four  previous studies reported an increased risk of pancreatic cancer with increasing intake of spirits and hard liquor. It has been suggested that nitrosamines  and cadmium  in different types of liquor and spirits may contribute to the increased risk of pancreatic cancer in high consumers of these beverages, but alcoholic beverages are not important dietary sources of these two compounds. Due to the number of tests in our analysis, our findings might as well be due to chance or to residual confounding due to unaccounted for characteristics of subjects who consume high amounts of spirits/liquor. Subjects who consume high amounts of liquor and spirits are also often heavy smokers. Therefore, residual confounding by smoking might be an alternative explanation of our results, but our finding remained virtually unchanged when excluding current smokers and those who quit up to ten years ago. EPIC includes several European countries with different alcohol consumption patterns, e. g. predominantly wine consuming countries in Southern Europe. However, effects for different types of alcoholic beverages were similar when the analyses were restricted to countries with specific drinking patterns (data not shown). Further studies on the role of alcohol in non-smokers to remove the issue of confounding by smoking and studies on the role of spirits/liquor are warranted.
The strengths of this study include its prospective design, the wide range of ethanol intake, the assessment of past alcohol consumption for the majority of the cohort, and the possibility to account for a large number of potential confounders. However, taking into account smoking, history of diabetes, height, weight, as well as education, physical activity, and energy intake from non-alcohol sources did not appreciably change the results of our study, which was also observed in a previous study . Alcohol consumption was self-reported via questionnaire and might, thus, be affected by measurement error. However, the information of alcohol consumption has been shown to be valid and reliable in country-specific validation studies [38, 39] for most countries, with the exception of Norway, where an underestimation of alcohol consumption by the FFQ was observed . EPIC was planned as a multi-center cohort study with a common core protocol to ensure a standardized collection of study information and a detailed protocol for the collection and standardization of clinical and pathological data of cancer information has been developed .
In conclusion, there was no indication of a statistically significant association between ethanol intake and pancreatic cancer risk in the EPIC cohort.
European Commission: Public Health and Consumer Protection Directorate 1993–2004; Research Directorate-General 2005-; Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, German Federal Ministry of Education and Research; Danish Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of Health, Spanish Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra; the ISCIII Network RCESP (C03/09), Spain; Cancer Research UK; Medical Research Council, United Kingdom; Stroke Association, United Kingdom; British Heart Foundation; Department of Health, United Kingdom; Food Standards Agency, United Kingdom; Wellcome Trust, United Kingdom; Greek Ministry of Health; Greek Ministry of Education; Italian Association for Research on Cancer (AIRC); Italian National Research Council, Fondazione-Istituto Banco Napoli, Italy; Compagnia di San Paolo; Dutch Ministry of Public Health, Welfare and Sports; World Cancer Research Fund; Swedish Cancer Society; Swedish Scientific Council; Regional Government of Skåne, Sweden; Norwegian Cancer Society; Research Council of Norway; French League against Cancer (LNCC); National Institute for Health and Medical Research (INSERM), France; Mutuelle Générale de l’Education Nationale (MGEN), France; 3M Co, France; Gustave Roussy Institute (IGR), France; and General Councils of France